Profile data is unavailable for this security.
About the company
Starpharma Holdings Limited is an Australia-based biotechnology company specializing in advancing dendrimer technology. The Company's principal activities are focused on the research, development and commercialization of dendrimer technology for pharmaceutical and healthcare applications. The Company's portfolio of dendrimer-based products includes three clinical-stage dendrimer enhanced product (DEP) assets, preclinical radiopharmaceutical assets, research collaborations, and three commercially marketed over the counter (OTC) products. Its clinical-stage assets, DEP SN38, DEP cabazitaxel, and DEP docetaxel, are dendrimer-based chemotherapeutic drugs. Additionally, the Company has a preclinical pipeline of DEP radiopharmaceuticals in development. It also manufactures and sells SPL7013 (astodrimer sodium) proprietary products: VivaGel BV, Viraleze nasal spray, and VivaGel condom. The Company has applied its DEP technology to the innovative area of antibody-drug conjugates.
- Revenue in AUD (TTM)5.85m
- Net income in AUD-9.99m
- Incorporated1997
- Employees50.00
- LocationStarpharma Holdings Ltd4-6 Southampton Crescent, AbbotsfordMELBOURNE 3067AustraliaAUS
- Phone+61 38532-2700
- Fax+61 39510-5955
- Websitehttps://www.starpharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Inoviq Ltd | 959.32k | -6.93m | 46.46m | 85.00 | -- | 2.20 | -- | 48.43 | -0.0623 | -0.0623 | 0.0086 | 0.1497 | 0.0478 | 3.73 | 0.6725 | -- | -34.52 | -43.01 | -37.36 | -45.87 | 87.45 | 89.08 | -722.62 | -1,543.44 | 5.72 | -- | 0.022 | -- | 21.17 | 57.69 | -5.77 | -- | -- | -- |
| Medical Developments International Ltd | 39.06m | 94.00k | 51.26m | 68.00 | 541.67 | 0.9302 | 15.55 | 1.31 | 0.0008 | 0.0008 | 0.3469 | 0.4891 | 0.6221 | 1.06 | 5.31 | -- | 0.1497 | -16.68 | 0.1738 | -18.92 | 75.35 | 72.70 | 0.2407 | -47.08 | 3.33 | -- | 0.0349 | -- | 17.82 | 11.30 | 100.23 | -24.33 | -34.91 | -- |
| Neurizon Therapeutics Ltd | 1.88m | -16.59m | 64.04m | 52.00 | -- | 16.51 | -- | 34.03 | -0.0334 | -0.0334 | 0.0038 | 0.0056 | 0.2431 | -- | 203.57 | -- | -214.34 | -65.69 | -254.22 | -74.86 | -- | -- | -881.68 | -368.00 | -- | -- | 0.00 | -- | -- | -- | -86.45 | -- | -44.79 | -- |
| Radiopharm Theranostics Ltd | 3.63m | -38.34m | 77.97m | 14.00 | -- | 1.16 | -- | 21.46 | -0.0179 | -0.0179 | 0.0017 | 0.0189 | 0.0458 | -- | 0.6382 | 259,530.70 | -48.38 | -- | -59.58 | -- | 1.08 | -- | -1,055.27 | -- | -- | -7.52 | 0.00 | -- | 1,114.26 | -- | 20.04 | -- | -- | -- |
| Biome Australia Ltd | 18.49m | 214.66k | 91.27m | 30.00 | 440.86 | 19.35 | 199.88 | 4.94 | 0.0009 | 0.0009 | 0.0833 | 0.0212 | 1.83 | 2.39 | 5.14 | -- | 2.12 | -43.09 | 5.42 | -74.65 | 61.27 | 60.84 | 1.16 | -31.29 | 1.02 | 1.80 | 0.3966 | -- | 41.43 | 80.32 | 112.85 | -- | 2.18 | -- |
| Vita Life Sciences Ltd | 85.60m | 9.31m | 142.01m | 124.00 | 15.71 | 2.76 | 29.33 | 1.66 | 0.1655 | 0.1655 | 1.52 | 0.9427 | 1.20 | 2.30 | 6.65 | -- | 13.05 | 15.71 | 17.96 | 22.24 | 60.34 | 59.82 | 10.87 | 12.15 | 2.21 | -- | 0.0409 | 47.99 | 8.28 | 13.37 | -3.26 | 22.87 | 29.67 | 21.67 |
| Recce Pharmaceuticals Ltd | 7.70m | -21.43m | 170.62m | -- | -- | -- | -- | 22.14 | -0.0899 | -0.0899 | 0.0325 | -0.0106 | 0.8203 | -- | 25.91 | -- | -228.15 | -150.15 | -- | -318.01 | -- | -- | -278.12 | -340.57 | -- | -17.98 | 1.49 | -- | 47.14 | 46.35 | -21.33 | -- | 34.71 | -- |
| Starpharma Holdings Ltd | 5.85m | -9.99m | 205.76m | 50.00 | -- | 10.79 | -- | 35.17 | -0.024 | -0.024 | 0.014 | 0.0454 | 0.188 | 0.5663 | 0.9444 | -- | -32.10 | -26.74 | -39.68 | -32.74 | 79.08 | 75.64 | -170.77 | -259.38 | 3.95 | -- | 0.1122 | -- | -40.04 | -2.25 | -22.35 | -- | -19.60 | -- |
| Mayne Pharma Group Ltd | 413.01m | -90.07m | 212.86m | 450.00 | -- | 0.5749 | -- | 0.5154 | -1.14 | -1.19 | 5.22 | 4.56 | 0.3828 | 2.57 | 2.42 | 917,797.80 | -8.35 | -15.32 | -11.61 | -20.87 | 61.06 | 53.04 | -21.81 | -64.51 | 1.16 | -- | 0.1003 | -- | 4.44 | -2.04 | 46.58 | -- | -9.26 | -- |
| Botanix Pharmaceuticals Ltd | 5.76m | -86.40m | 221.64m | 1.00 | -- | 2.71 | -- | 38.50 | -0.0466 | -0.0466 | 0.0031 | 0.0415 | 0.0477 | 0.2477 | 3.48 | -- | -71.53 | -50.27 | -81.16 | -56.02 | 36.99 | -- | -1,500.65 | -1,888.17 | 2.87 | -- | 0.2226 | -- | 856.64 | 102.14 | -522.91 | -- | 63.43 | -- |
| Clinuvel Pharmaceuticals Ltd | 95.02m | 36.17m | 532.13m | 16.00 | 14.77 | 2.21 | 14.25 | 5.60 | 0.7177 | 0.7177 | 1.89 | 4.80 | 0.3779 | 0.1857 | 3.54 | -- | 14.39 | 17.33 | 16.06 | 19.40 | 98.10 | 101.95 | 38.07 | 38.23 | 9.34 | -- | 0.0022 | 7.22 | -0.5085 | 23.46 | 1.50 | 19.17 | -19.60 | 14.87 |
| Holder | Shares | % Held |
|---|---|---|
| Allianz Global Investors Asia Pacific Ltd.as of 31 Oct 2025 | 37.80m | 9.00% |
| Allan Gray Australia Pty Ltd.as of 05 Sep 2024 | 20.84m | 4.96% |
| FIL Investment Management (Hong Kong) Ltd.as of 31 Dec 2025 | 11.96m | 2.85% |
| FIL Pensions Managementas of 30 Jun 2025 | 2.06m | 0.49% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 0.00 | 0.00% |
| ICM Investment Management Ltd.as of 30 Sep 2025 | 0.00 | 0.00% |
